Figures & data
Table 1. Properties of ADC and dosing regimen in first-in-man studies
Table 2. Comparative PK parameters of ADCs at MTD or nearest dose level, at Cycle 1
Table 3. Incidence of patients with persistent anti-therapeutic antibody response, following ADC administration in Phase 1
Figure 1. ADC dose ranges and maximum tolerated doses in first-in-humans studies. Gray symbol: MTD; open symbol: MTD not reached.
Figure 2. ADC dose escalation profiles in first-in-human studies.
Figure 3. Dose-exposure relationship for ADC administered every 3 wk.
Figure 4. Effect of dose on ADC clearance, by target antigen type (HT, hematological tumor; ST, solid tumors. (Boxes indicate maximum tolerated dose in mg/kg)
Figure 5. Unconjugated drug plasma exposure vs. ADC plasma exposure.
